We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited s... Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. Show more
Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “SO, Have You Found It?” campaign. This initiative spotlights the resilience of ar...
KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications Bristol Myers Squibb (NYSE: BMY) today annou...
The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan and Switzerland and received a positive CHMP Opinion b...
Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...
Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2024 on Thursday, April 25, 2024. Company executives will review financial results and address inquiries from investors ...
In the Phase 3 CheckMate -901 trial, Opdivo with cisplatin and gemcitabine demonstrated a statistically significant improvement in overall survival and progression-free survival compared to cisplatin-...
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2024. Samit Hirawat, M.D., executive vice president, chief medical offi...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.49 | -4.57384276267 | 54.44 | 55.035 | 51.53 | 39410305 | 52.46727471 | CS |
4 | 2.06 | 4.12908398477 | 49.89 | 55.035 | 49.535 | 20229063 | 52.16870283 | CS |
12 | -0.46 | -0.877695096356 | 52.41 | 55.035 | 47.58 | 17127427 | 50.9382578 | CS |
26 | -6.61 | -11.287568306 | 58.56 | 59.46 | 47.58 | 15265621 | 51.82918488 | CS |
52 | -14.71 | -22.0672067207 | 66.66 | 71.065 | 47.58 | 12282206 | 56.40905093 | CS |
156 | -10.12 | -16.3041727082 | 62.07 | 81.435 | 47.58 | 11525142 | 64.29838186 | CS |
260 | 1.94 | 3.87922415517 | 50.01 | 81.435 | 41.19 | 12430652 | 60.75766592 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: 1-888-992-3836 | help@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |